Evaluation of Plerixafor (Mozobil ™, AMD3100) in Combination With Chemotherapy and G-CSF for CD34+ Cell Mobilization
Study is ongoing; no interim analysis.
Interventional
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Proportion of patients achieving the target number of either 5 x 106 (lymphoma) or 10 x 106 (myeloma) of CD34+ cells/kg in a single day of apheresis
Within the first 4 days following the first dose of Plerixafor
No
Edmund Waller, MD, PhD
Principal Investigator
Emory University Winship Cancer Institute
United States: Institutional Review Board
WCI1671-09
NCT01095757
March 2010
November 2013
Name | Location |
---|---|
Emory University Winship Cancer Institute | Atlanta, Georgia 30322 |